Comparative Pharmacology
Head-to-head clinical analysis: AMIKIN versus NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKIN versus NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC.
AMIKIN vs NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Neomycin is an aminoglycoside that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis. Polymyxin B is a polypeptide that disrupts bacterial cell membrane permeability by interacting with phospholipids. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier in peptidoglycan biosynthesis.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
Apply thin layer to affected area 2-3 times daily. For ophthalmic use: 1-2 drops in affected eye every 4 hours, or 1/2 inch ribbon of ointment in conjunctival sac 2-3 times daily.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
Neomycin: 2-3 h (terminal), prolonged in renal impairment; polymyxin B: 6-7 h (terminal), extended in renal failure; bacitracin: 1.5 h (if absorbed), not clinically relevant due to minimal absorption.
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Renal: ~90% of absorbed neomycin and polymyxin B; bacitracin zinc: minimal systemic absorption, excreted primarily in feces. For neomycin: ~99% fecal after oral; polymyxin B: ~60% renal, rest biliary; bacitracin: nearly 100% renal if absorbed.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic